To address whether EZH2 might have oncogenic activity, we recently deleted EZH2 and SUZ12 in mouse and human G3 MBs by TALEN and CRISPR-Cas9 gene editing approaches [33]. This evidence concerns the gene EZH2 and Mobius syndrome.